MANKIND vs WINDLAS: Stock Comparison
MANKIND PHARMA is the larger company by market capitalisation. MANKIND PHARMA shows a lower P/E, a higher ROE and a higher net margin, while WINDLAS BIOTECH shows a higher dividend yield, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
MANKIND leads 7; WINDLAS leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | MANKIND | WINDLAS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | MANKIND | WINDLAS |
|---|---|---|
| Live Price | ₹2,280 | ₹1,129.25 |
| Day Change | 1.86% | -0.01% |
| Volume | 5.31 L | 66,749 |
| 52-Week High | ₹2,674 | ₹1,181.9 |
| 52-Week Low | ₹1,909.7 | ₹697.4 |
| Distance from 52W High | -14.73% | -4.45% |
Valuation
| Metric | MANKIND | WINDLAS |
|---|---|---|
| Market Cap | ₹94,039 Cr | ₹2,359 Cr |
| P/E Ratio | 45.89x | 49.39x |
| P/B Ratio | 5.77x | 4.15x |
| EPS | ₹13.9 | ₹8.55 |
| Book Value | ₹401 | ₹281.47 |
| Dividend Yield | 0% | 0.55% |
Growth
| Metric | MANKIND | WINDLAS |
|---|---|---|
| Revenue Growth (TTM YoY) | 11.8% | 17.7% |
| EPS Growth (TTM YoY) | 31.7% | -2.6% |
| Qtr Sales Growth | 35.98% | 4.03% |
| Qtr Profit Growth | 2.79% | 10.22% |
Profitability & Leverage
| Metric | MANKIND | WINDLAS |
|---|---|---|
| ROE | 12.41% | 11.44% |
| ROCE | 11.87% | 11.95% |
| Net Margin | 13.34% | 7.35% |
| Operating Margin | 27.68% | 10.15% |
| Debt to Equity | 0.34x | 0.05x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | MANKIND | WINDLAS |
|---|---|---|
| Promoter Holding | 72.63%▼ 0.03 pp | 63.31%▲ 1.41 pp |
| FII Holding | 9.45%▼ 0.79 pp | 2.04%▲ 1.44 pp |
| DII Holding | 15.39%▲ 0.93 pp | 9.84%▼ 1.97 pp |
| Public Holding | 2.53%▼ 0.11 pp | 24.8%▼ 0.9 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: MANKIND PHARMA and WINDLAS BIOTECH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.